Vaccine News and Research

Latest Vaccine News and Research

Cholera deaths in Haiti top 2,500, health ministry says

The Haitian health ministry on Sunday said there had been 2,535 cholera deaths since the outbreak hit in mid-October, "dashing hopes the fatality rate might be beginning to taper off," Agence France-Presse reports.

21 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Researchers recommend 'watchful waiting' over antibiotic treatment for many children with ear infections

As middle ear infections increase during the winter months, researchers from Ben-Gurion University of the Negev (BGU) suggest that in many cases the most appropriate treatment is "watchful waiting" instead of using antibiotics immediately.

20 Dec 2010

Research roundup: Gender differences in health spending; How the states could fare under the new law; Increased Medicare premiums

Health Affairs: Pronounced Gender And Age Differences Are Evident In Personal Health Care Spending Per Person - This paper examines health care spending by men and women in 2004, including comparisons "by age group, goods and services consumed, and payers, and an analysis of some of the most frequently cited health conditions and treatments associated with that spending."

20 Dec 2010

Walgreens partners with HHS to provide over $10M worth of flu shots for people without adequate health insurance

Walgreens and the U.S. Department of Health and Human Services (HHS) are teaming up in an effort to make 2011 a healthier New Year for those without adequate health insurance.

20 Dec 2010

Human fetal immune system entirely different from adult immune system

UCSF researchers have shown for the first time that the human fetal immune system arises from an entirely different source than the adult immune system, and is more likely to tolerate than fight foreign substances in its environment.

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Genome is one more factor to blame for unwanted pounds

In addition to fast food, desk jobs, and inertia, there is one more thing to blame for unwanted pounds-our genome, which has apparently not caught up with the fact that we no longer live in the Stone Age.

16 Dec 2010

PCSBI issues 18 recommendations in emerging field of synthetic biology

The Presidential Commission for the Study of Bioethical Issues today released its first report-a wide-ranging review of the emerging field of synthetic biology-issuing 18 recommendations including a call for coordinated federal oversight of scientists working in both large institutions and smaller settings.

16 Dec 2010

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, announces the award of a grant from the ANR (the French state Research National Agency) and a label award from both "Clusters of excellence", Medicen Paris Region and Atlanpole, for two new applications of its mucoadhesive Lauriad™ technology. These projects are dedicated to the development of new biological products based on the Lauriad™ technology allowing mucous penetration of a biologically active compound.

16 Dec 2010

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.

16 Dec 2010

Opinions: Kangaroo care; NTDs, Women's health

New York Times contributing writer Tina Rosen, on the newspaper's "Opinionator" blog, examines the success of a system known as kangaroo care, which has helped to improve the survival rates of premature infants by using skin-to-skin contact with mothers in place of incubators in low-resource settings. The post notes the potential value of such a strategy in poor countries "where pregnant women are unlikely to get the food and care they need," and "low birth weight babies are very common."

16 Dec 2010

NIH grants $7.5 million for researchers to develop novel compounds in treating nicotine addiction

The Scripps Research Institute and the University of California, San Diego, School of Medicine have been awarded approximately $7.5 million over five years to develop novel compounds that could eventually become drug candidates for the treatment of nicotine dependence, and possibly other drug addictions.

16 Dec 2010

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

A synthetic derivative of the curry spice turmeric, made by scientists at the Salk Institute for Biological Studies, dramatically improves the behavioral and molecular deficits seen in animal models of ischemic stroke and traumatic brain injury.

16 Dec 2010

Clinical Investigation – ground-breaking new launch from Future Science

In recognition of the methodology, progress and outcome of clinical trials, Future Science has announced the launch of the definitive title Clinical Investigation. The journal is the latest addition to the Future Science’s collection of titles addressing those areas that most impact our daily lives (available at www.future-science.com). Future Science is part of London-based Future Science Group.

15 Dec 2010

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.

15 Dec 2010

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines.

15 Dec 2010

Reuters looks at cost-effectiveness of pursuing malaria vaccine, eradication

Reuters examines the effort to create an effective malaria vaccine and asks: "[I]s the vaccine - and the global health community's aim of completely eradicating a disease that kills a child every 45 seconds - really worth the money?"

15 Dec 2010

Vaccine News and Research

Latest Vaccine News and Research

Cholera deaths in Haiti top 2,500, health ministry says

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Researchers recommend 'watchful waiting' over antibiotic treatment for many children with ear infections

Research roundup: Gender differences in health spending; How the states could fare under the new law; Increased Medicare premiums

Walgreens partners with HHS to provide over $10M worth of flu shots for people without adequate health insurance

Human fetal immune system entirely different from adult immune system

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Genome is one more factor to blame for unwanted pounds

PCSBI issues 18 recommendations in emerging field of synthetic biology

BioAlliance wins grant and award for new applications of mucoadhesive Lauriad technology

CEL-SCI receives Ukraine government approval for Multikine Phase III clinical trial in head and neck cancer

Opinions: Kangaroo care; NTDs, Women's health

NIH grants $7.5 million for researchers to develop novel compounds in treating nicotine addiction

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Clinical Investigation – ground-breaking new launch from Future Science

Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

Reuters looks at cost-effectiveness of pursuing malaria vaccine, eradication

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Vaccine News and Research

Latest Vaccine News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in